Modality
Bispecific Ab
MOA
BCMA ADC
Target
WRN
Pathway
Notch
Celiac
Development Pipeline
Preclinical
~Jun 2020
→ ~Sep 2021
Phase 1
Dec 2021
→ Feb 2031
Phase 1Current
NCT08156551
101 pts·Celiac
2021-12→TBD·Active
NCT03472147
1,985 pts·Celiac
2025-07→2031-02·Completed
2,086 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-02-014.8y awayPh2 Data· Celiac
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1/2
Active
P1/2
Complet…
Catalysts
Ph2 Data
2031-02-01 · 4.8y away
Celiac
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08156551 | Phase 1/2 | Celiac | Active | 101 | ACR20 |
| NCT03472147 | Phase 1/2 | Celiac | Completed | 1985 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Tixatapinarof | Recursion | Approved | FGFR |